ÐÓ°ÉÔ­´´

Aqemia, a Paris-based drug discovery platform, demonstrates strong business potential by addressing the slow and costly process of developing new drugs. With a B2B model targeting pharmaceutical companies, Aqemia aims to expedite research and reduce expenses. The company leverages advanced computational techniques to accelerate drug discovery, distinguishing itself from traditional laboratory methods and older computational approaches. Backed by investors such as Wendel Growth and Bpifrance, Aqemia is positioned to disrupt the market, offering a more efficient pathway for pharma companies to bring new drugs to market faster.